JP2003517423A5 - - Google Patents

Download PDF

Info

Publication number
JP2003517423A5
JP2003517423A5 JP2000504866A JP2000504866A JP2003517423A5 JP 2003517423 A5 JP2003517423 A5 JP 2003517423A5 JP 2000504866 A JP2000504866 A JP 2000504866A JP 2000504866 A JP2000504866 A JP 2000504866A JP 2003517423 A5 JP2003517423 A5 JP 2003517423A5
Authority
JP
Japan
Prior art keywords
adenosine
ethyluronamide
substituted
alkyl
echiruuronamido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000504866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003517423A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/016053 external-priority patent/WO1999006053A1/en
Publication of JP2003517423A publication Critical patent/JP2003517423A/ja
Publication of JP2003517423A5 publication Critical patent/JP2003517423A5/ja
Pending legal-status Critical Current

Links

JP2000504866A 1997-07-29 1998-07-29 アデノシンレセプターモジュレーターとしてのn6−置換アデノシン−5′−ウロナミド Pending JP2003517423A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5406497P 1997-07-29 1997-07-29
US60/054,064 1997-07-29
PCT/US1998/016053 WO1999006053A1 (en) 1997-07-29 1998-07-29 N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators

Publications (2)

Publication Number Publication Date
JP2003517423A JP2003517423A (ja) 2003-05-27
JP2003517423A5 true JP2003517423A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=21988552

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000504866A Pending JP2003517423A (ja) 1997-07-29 1998-07-29 アデノシンレセプターモジュレーターとしてのn6−置換アデノシン−5′−ウロナミド

Country Status (5)

Country Link
EP (1) EP1019427A1 (cg-RX-API-DMAC7.html)
JP (1) JP2003517423A (cg-RX-API-DMAC7.html)
AU (1) AU8764398A (cg-RX-API-DMAC7.html)
CA (1) CA2296485A1 (cg-RX-API-DMAC7.html)
WO (1) WO1999006053A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050047A1 (en) * 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
HUP0103836A3 (en) 1998-06-02 2003-05-28 Osi Pharmaceuticals Inc Uniond Pyrrolo[2,3d]pyrimidine compositions and their use
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
ES2269217T3 (es) 1999-12-02 2007-04-01 Osi Pharmaceuticals, Inc. Compuestos especificos para los receptores a1, a2a y a3 de adenosina y sus usos.
WO2002035231A1 (en) * 2000-10-26 2002-05-02 Actar Ab Screening method using a g coupled receptor associated with a specific g protein
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
CA2434906C (en) 2001-01-16 2008-08-19 Can-Fite Biopharma Ltd. Use of an adenosine a3 receptor agonist for inhibition of viral replication
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
JP2005529062A (ja) 2001-11-30 2005-09-29 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アデノシンa1及びa3受容体に特異的な化合物とその使用
DE60236458D1 (de) 2001-12-20 2010-07-01 Osi Pharm Inc Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
KR20040068317A (ko) 2001-12-20 2004-07-30 오에스아이 파마슈티컬스, 인코포레이티드 피리미딘 a₂b 선택성 길항 화합물, 그의 합성 방법 및용도
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
DE602004027409D1 (de) * 2003-10-21 2010-07-08 Inspire Pharmaceuticals Inc Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
ES2432113T3 (es) * 2004-07-28 2013-11-29 Can-Fite Biopharma Ltd. Agonistas del receptor de adenosina A3 para el tratamiento de trastornos del ojo seco, incluido el síndrome de Sjogren
EP1798233A1 (en) * 2005-12-19 2007-06-20 Faust Pharmaceuticals Pyrrolo[1,2-a]quinoxaline derivatives as Adenosine A3 receptor modulators and uses thereof
EP2227234B1 (en) 2007-10-15 2014-05-07 Can-Fite Biopharma Ltd. Method for inducing hepatocyte proliferation and uses thereof
WO2010134067A1 (en) 2009-05-17 2010-11-25 Can-Fite Biopharma Ltd. A3 adenosine receptor agonists for the reduction of intraocular pressure
US9199102B2 (en) 2009-07-21 2015-12-01 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
US20130045943A1 (en) 2010-03-03 2013-02-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of A3ar agonists for the treatment of uveitis
MX378538B (es) 2012-08-09 2025-03-10 Can Fite Biopharma Ltd Ligandos del receptor de adenosina a3 para su uso en el tratamiento de una disfuncion sexual.
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
IL254535A0 (en) 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina An a3 adenosine receptor ligand for use for reducing level of adipocytes
IT202300014340A1 (it) 2023-07-10 2025-01-10 Consiglio Nazionale Ricerche Trattamento di malattie associate alla disfunzione del gene ocrl.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310731A (en) * 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
WO1998050047A1 (en) * 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists

Similar Documents

Publication Publication Date Title
JP2013516501A (ja) マイボーム腺機能障害を治療する方法
CA2798259A1 (en) Nuclear receptor binding agents
CA2376158A1 (en) Use of selective estrogen receptor modulators in the manufacture of medicaments for treating and/or suppressing weight gain
JP2006520801A5 (cg-RX-API-DMAC7.html)
KR20170068629A (ko) 항코넥신제로서의 플레카이니드의 용도 및 향정신성 약물 효과를 증강시키는 방법
JP2003509349A5 (cg-RX-API-DMAC7.html)
MXPA06006696A (es) (s)-2-n-propilamino-5-hidroxitetralina como un agonista-d3.
KR960041168A (ko) 베타-아드레날린 효능성 작용물질
JP4923141B2 (ja) アデノシン誘導体を有効成分として含有する緑内障治療剤
JP2004537597A5 (cg-RX-API-DMAC7.html)
RU2012110380A (ru) Новое производное 5-фторурацила
JP2017132802A (ja) ヒストンアセチルトランスフェラーゼ活性剤の使用
US20110123510A1 (en) Methods of Affecting Biological Function Through Circadian Clock Feedback Cycle by NAMPT-Mediated NAD+ Biosynthesis
WO2008087461B1 (en) Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis
CN1950076A (zh) 含安溴索的局部制剂
CA2464471A1 (en) Method of treating depression with delta receptor agonist compounds
US20150072935A1 (en) Composition and external application for acceleration of muscle differentiation and improving of muscle mass
CN1443071A (zh) 具有神经保护作用的7-β-羟基类固醇
JP5754885B2 (ja) 経皮または経粘膜投与用組成物
JP4246997B2 (ja) 糖尿病由来虚血性心疾患の治療及び/または予防剤
CN109310669B (zh) 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途
EP1773307B1 (en) Compound formulations of 2-amino-1,3-propanediol compounds
JP2000502681A (ja) 生物学的に活性なベンゾチアゾロンエタンアミン
JP2007518673A5 (cg-RX-API-DMAC7.html)
US7671091B2 (en) Penis enlargement